News Detail
New Delhi, 5 March 2024: The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major Astrazeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug L......
View Details
Source : Pharmabiz
Subject Expert Committee
SEC
Astrazeneca
anti-hyperkalaemia
Lokelma
sodium zirconium cyclosilicate
end-stage kidney disease
ESKD
chronic haemodialysis
Related News
- Authorities Seize Counterfeit Medicines in UP Raid (20-01-2025)
- Illegal Performance-Enhancing Drugs Seized in Hyderabad Gym Raid (20-01-2025)
- EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 (20-01-2025)
- IPC to host 'World Pharmacopoeia meet' next month (20-01-2025)
- Immuneel Therapeutics launches low cost treatment for blood cancer (20-01-2025)
- Video clip of IIT Madras Director Kamakoti favouring 'Gomutra' goes viral (20-01-2025)
- Puducherry scientist develops high-yielding pepper variety (19-01-2025)
- Pharma firm raided in Baddi by ANTF again (19-01-2025)
- 2.70 lakh Narcotic Pills recovered in Sirsa, driver detained, handed over to DCO (19-01-2025)
- Arrest warrant for Baba Ramdev and Balakrishna (19-01-2025)